End of the line for Sanofi’s SERD amcenestrant as it fails first-line trial
amcenestrant, AstraZeneca, breast cancer, camizestrant, elacestrant, Eli Lilly, giridestrant, imlunestrant, Menarini Group, Oncology, Radius Health, Roche, Sanofi, serd
0 Comment